Sponsor Pipeline

Qiming Wang Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
0
Recruiting
2
Disease Areas
Active Trials by Phase
Phase 4
1
Phase 2
1
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT07671560 Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant… ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib Not Yet Recruiting
Phase 2
NCT06971406 High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the… Non Small Cell Lung Cancer Not Yet Recruiting
Not specified
NCT06926803 A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With… Lung Cancer (NSCLC) Active, Not Recruiting
Disease Areas
Get alerts when Qiming Wang's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free